A side-by-side comparison of two Healthcare investors: Catalio Capital Management (Power Score 82/100) and Vivo Capital (Power Score 83/100), both ranked among the most active firms tracked in this category.
| Catalio Capital Management | Vivo Capital | |
|---|---|---|
| Power Score™ | 82/100 | 83/100 |
| Assets Managed | $2B (the homepage prints "$2B In assets under management *as of 10/01/2025"; the raw date form is carried here because for a US filer 10/01/2025 reads as 1 October 2025) | $6.1B ("Active AUM" as of Q4 2025, the label the firm uses on its own homepage; it separately stated approximately $5.3B of regulatory assets under management in its 7 May 2025 fund-close announcement) |
| Founded | 2020 | 1996 |
| Headquarters | New York, NY | Palo Alto, CA |
| Sectors | Healthcare, Biotech, Medical Devices, Diagnostics, Life Sciences, Data | Healthcare, Biotech, Pharmaceuticals, Life Sciences, Healthtech |
Catalio Capital Management is an SEC-registered investment adviser (CRD 310374, SEC file 801-121976) that describes itself as focused on the full lifecycle of innovative healthcare investing, across private, public and credit markets. It runs four stated strategies: Private Equity and Venture Capital, investing in privately held innovative healthcare companies at all stages from inception to IPO; Structured Opportunities, providing senior-secured financing to healthcare innovators; Public Equities, a fundamental equity long/short strategy investing in global healthcare equities across innovative drugs, devices, diagnostics and data; and Co-Investments offering limited partners direct access to selected deals. The firm operates from New York, Washington DC and London, and states that it works with a network of more than 45 Venture Partners who hold equity interests across all Catalio strategies. It is a multi-strategy healthcare investment manager rather than a pure venture partnership.
View full Catalio Capital Management profile →Vivo Capital describes itself as a global healthcare specialist running a multi-strategy investment platform that covers venture capital, private equity and public equity. Its investment strategy page names three distinct strategies: the Vivo Innovation Fund, which invests in venture-stage companies developing healthcare technologies or products; Vivo Capital Private Equity, which combines growth capital for companies at commercial inflection points with a buyout strategy covering leveraged buyouts, management buyouts, spin-offs and restructurings; and the Vivo Opportunity Fund, a long-only strategy investing primarily in global public equities of small and mid-cap biotechnology, pharmaceutical, healthcare and life science companies through follow-ons, PIPEs, registered directs and IPOs. The firm states it has invested in over 460 healthcare companies and operates from Palo Alto with offices in China and a presence in Singapore.
View full Vivo Capital profile →